Scope
Description
This tender is for medicines which are shortly due to lose their patent exclusivity, including but not limited to Ferric Carboxymaltose; Pazopanib; Denosumab; Apremilast
Commercial tool
Establishes a framework
Total value (estimated)
- £15,902,104 excluding VAT
- £19,082,525 including VAT
Above the relevant threshold
Contract dates (estimated)
- 1 March 2026 to 29 February 2028
- Possible extension to 28 February 2030
- 4 years
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKL - Wales
Engagement
Engagement deadline
18 November 2025
Engagement process description
This notice is being issued to advise suppliers of a forthcoming opportunity that is due to be published by Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts).
There is no formal engagement process for this opportunity. Any suppliers who may like more information on this opportunity before the tender is published please contact Jennifer Tresilian (jennifer.tresilian@wales.nhs.uk).
Participation
Particular suitability
Small and medium-sized enterprises (SME)
Submission
Publication date of tender notice (estimated)
26 November 2025
Contracting authority
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
- NHS Organisation Data Service: RQF
Imperial Park Unit 5, Celtic Way
Newport
NP10 8BE
United Kingdom
Contact name: Jennifer Tresilian
Telephone: +442921501383
Email: jennifer.tresilia@wales.nhs.uk
Website: http://nwssp.nhs.wales/ourservices/procurement-services/
Region: UKL21 - Monmouthshire and Newport
Organisation type: Public authority - central government
Devolved regulations that apply: Wales